Abstract:Acute myeloid leukemia (AML) is an aggressive haematological cancer characterized phenotypically by the rapid clonal growth of myeloid cells and an accumulation of immature blasts. Although major progress has been made in identifying different genetic and molecular AML subgroups, treatment and long-term patient outcomes have not changed significantly over the past four decades. Recently, venetoclax (ABT-199), a selective BCL-2 inhibitor, has been approved for the treatment of older patients with AML. However, drug resistance and disease progression on venetoclax as well as the inherent resistance of leukemic stem cells (LSCs) to therapy pose significant clinical challenges. One candidate target for improved therapies is AXL, a member of the TYRO3/AXL/MER (TAM) family of receptor tyrosine kinases that is elevated in AML cells and LSCs, and associated with poor prognosis in AML. To test whether targeting of AXL is a feasible treatment strategy for AML, in particular to eradicate LSCs, we developed a potent and selective AXL inhibitor. We show that AXL inhibition targets AML cells with high AXL expression and synergizes with venetoclax decreasing the viability of primitive AML patient cells and reducing their clonal short- and long-term colony assay outputs compared to single or control treatments. Moreover, a combination of AXL inhibition and venetoclax treatment was able to target LSCs and AML blasts in two different preclinical patient-derived xenotransplantation (PDX) models. Single-cell RNA-sequencing and functional validation studies revealed that AXL inhibition perturbs oxidative metabolism and differentially targets signaling pathways to synergize with venetoclax in leukemic cell killing. Importantly, the combination of AXL inhibition plus venetoclax was not toxic to normal BM cells from healthy donors. Hence, our findings identify a promising, improved and specific treatment strategy for AML. Acute myeloid leukemia (AML) is an aggressive haematological cancer characterized phenotypically by the rapid clonal growth of myeloid cells and an accumulation of immature blasts. Although major progress has been made in identifying different genetic and molecular AML subgroups, treatment and long-term patient outcomes have not changed significantly over the past four decades. Recently, venetoclax (ABT-199), a selective BCL-2 inhibitor, has been approved for the treatment of older patients with AML. However, drug resistance and disease progression on venetoclax as well as the inherent resistance of leukemic stem cells (LSCs) to therapy pose significant clinical challenges. One candidate target for improved therapies is AXL, a member of the TYRO3/AXL/MER (TAM) family of receptor tyrosine kinases that is elevated in AML cells and LSCs, and associated with poor prognosis in AML. To test whether targeting of AXL is a feasible treatment strategy for AML, in particular to eradicate LSCs, we developed a potent and selective AXL inhibitor. We show that AXL inhibition targets AML cells with high AXL expression and synergizes with venetoclax decreasing the viability of primitive AML patient cells and reducing their clonal short- and long-term colony assay outputs compared to single or control treatments. Moreover, a combination of AXL inhibition and venetoclax treatment was able to target LSCs and AML blasts in two different preclinical patient-derived xenotransplantation (PDX) models. Single-cell RNA-sequencing and functional validation studies revealed that AXL inhibition perturbs oxidative metabolism and differentially targets signaling pathways to synergize with venetoclax in leukemic cell killing. Importantly, the combination of AXL inhibition plus venetoclax was not toxic to normal BM cells from healthy donors. Hence, our findings identify a promising, improved and specific treatment strategy for AML.

Targeting AXL Kinase Sensitizes Leukemic Stem and Progenitor Cells to Venetoclax Treatment in Acute Myeloid Leukemia.

3125 – COMBINING VENETOCLAX TREATMENT WITH AXL KINASE INHIBITION TARGETS CANCER STEM AND PROGENITOR CELLS IN ACUTE MYELOID LEUKEMIA

AXL Inhibition Induces DNA Damage and Replication Stress in Non–Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors

Abivertinib Synergistically Strengthens the Anti‐leukemia Activity of Venetoclax in Acute Myeloid Leukemia in a BTK‐dependent Manner

Co‐Targeting C‐myc and Bcl‐2 by Oral Small Molecule Combination of WBC100 and Venetoclax Effectively Controls Acute Myeloid Leukemia in Preclinical Models

Targeting the GAS6/AXL Pathway with a Newly Developed AXL-Selective Inhibitor SLC-0211 for the Treatment of Acute Myeloid Leukemia

Combinatorial inhibition of focal adhesion kinase and BCL-2 enhances anti-leukemia activity of venetoclax in acute myeloid leukemia.

Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia

Bcl-2 inhibition combined with PPARα activation synergistically targets leukemic stem cell-like cells in acute myeloid leukemia

Novel AXL-targeted Agents Overcome FLT3 Inhibitor Resistance in FLT3-ITD+ Acute Myeloid Leukemia Cells

Lysosomal Acid Lipase A Modulates Leukemia Stem Cell Response to Venetoclax/tyrosine Kinase Inhibitor Combination Therapy in Blast Phase Chronic Myeloid Leukemia

Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia

AXL antibody and AXL-ADC mediate antitumor efficacy via targeting AXL in tumor-intrinsic epithelial-mesenchymal transition and tumor-associated M2-like macrophage

AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies

Enhancing the antileukemic activity of venetoclax against leukemia stem cells by targeting oxidative phosphorylation through dual inhibition of PI3K and HDAC.

Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation

Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance

Data from Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia

Abstract 2463: Enhancing the Antileukemic Activity of Venetoclax Against Leukemia Stem Cells by Targeting Oxidative Phosphorylation Through Dual Inhibition of PI3K and HDAC

NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia

Venetoclax Enhances DNA Damage Induced by XPO1 Inhibitors: A Novel Mechanism Underlying the Synergistic Antileukaemic Effect in Acute Myeloid Leukaemia